ISRCTN09560399 https://doi.org/10.1186/ISRCTN09560399

Evaluation of the bioavailability of bioactive wheat bran components

Submission date 17/09/2008	**Recruitment status** No longer recruiting	[_] Prospectively registered [_] Protocol [_] Statistical analysis plan [X] Results [_] Individual participant data
Registration date 04/12/2008	**Overall study status** Completed	
Last Edited 04/03/2016	**Condition category** Other	

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Prof Robert Welch

Contact details
Northern Ireland Centre for Food and Health (NICHE)
Biomedical Sciences
University of Ulster
Cromore Rd
Coleraine
United Kingdom
BT52 1SA
+44 (0)28 7032 4205
rw.welch@ulster.ac.uk

Additional identifiers

Study information

Scientific Title
Evaluation of the bioavailability of bioactive wheat bran components

Study objectives

Bioactive components present in minimally processed wheat grain fractions are available to the body and can be detected in the plasma and urine shortly after consumption.

Ethics approval required
Old ethics approval format

Ethics approval(s)
The study was approved by the University of Ulster Research Ethics Committee in July 2006 (ref: REC/06/0012).

Primary study design
Interventional

Study design
Randomised cross-over design on three occasions carried out in a single-centre

Study type(s)
Diagnostic

Health condition(s) or problem(s) studied
Chronic diseases, particularly cardiovascular disease and cancers

Interventions
1. Test-meal 1: 50 g wheat bran boiled in water with sugar
2. Test-meal 2: 50 g wheat aleurone boiled in water with sugar
3. Control-meal: 50 g refined wheat product

Test and control meals were balanced for energy, fibre and macronutrients.

Intervention Type
Drug

Phase
Not Specified

Drug/device/biological/vaccine name(s)
Bioactive wheat bran

Primary outcome(s)
1. Changes in plasma betaine, choline, folate, tocopherols and ferulic acid attributable to treatments, measured at baseline, 0.5 hours, 1 hour, 2 hours and 3 hours post-meal
2. Changes in urinary ferulic acid attributable to treatments, measured at baseline, 0.5 hours, 1 hour, 2 hours, 3 hours and 4 hours post-meal

Key secondary outcome(s)
1. Changes in plasma antioxidant activity attributable to treatments, measured at baseline, 0.5 hours, 1 hour, 2 hours and 3 hours post-meal
2. Changes in urinary antioxidant activity and phenolic activity attributable to treatments, measured at baseline, 0.5 hours, 1 hour, 2 hours, 3 hours and 4 hours post-meal

Completion date
31/05/2006

Eligibility

Key inclusion criteria
Healthy 18 - 40 year old men and women with Body Mass Index (BMI) between 18 and 30 kg/m^2.

Participant type(s)
Patient

Healthy volunteers allowed
No

Age group
Adult

Lower age limit
18 Years

Sex
All

Key exclusion criteria
1. Smokers
2. Individuals with diabetes
3. Pre-existing chronic disease
4. On any prescription medicine
5. Individuals who regularly take any vitamin or mineral supplement or did so in the 6 months prior to the study
6. Gluten or wheat intolerant individuals
7. Pregnant or lactating women
8. Individuals who have given blood to the Blood Transfusion Service (BTS) in the 6 months prior to the study

Date of first enrolment
01/04/2006

Date of final enrolment
31/05/2006

Locations

Countries of recruitment
United Kingdom

Northern Ireland

Study participating centre
Northern Ireland Centre for Food and Health (NICHE)
Coleraine
United Kingdom
BT52 1SA

Sponsor information

Organisation
European Commission (Belgium)

ROR
https://ror.org/00k4n6c32

Funder(s)

Funder type
Government

Funder Name
HEALTHGRAIN (Europe) - an integrated 6th framework European Union (EU) project (ref: FOOD-CT-2005-514008)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	17/02/2016		Yes	No
Study website	Study website	11/11/2025	11/11/2025	No	Yes